Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 11Active not recruiting 3Withdrawn 1Unknown 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Melanoma 40Carcinoma, Non-Small-Cell Lung 40Carcinoma, Renal Cell 30Urinary Bladder Neoplasms 15Squamous Cell Carcinoma of Head and Neck 15Lung Neoplasms 15Colorectal Neoplasms 15Stomach Neoplasms 13Pancreatic Neoplasms 13Neoplasms 13Neoplasm Metastasis 13Ovarian Neoplasms 11Sarcoma 10Hodgkin Disease 10Glioblastoma 10Carcinoma, Transitional Cell 10Rectal Neoplasms 9Triple Negative Breast Neoplasms 8Prostatic Neoplasms 8Kidney Neoplasms 8Carcinoma, Hepatocellular 8Small Cell Lung Carcinoma 7Esophageal Neoplasms 7Colonic Neoplasms 7Breast Neoplasms 7Head and Neck Neoplasms 6Skin Neoplasms 5Lymphoma, Large B-Cell, Diffuse 5Carcinoma, Neuroendocrine 5Carcinoma, Merkel Cell 5

Interventions

Oxaliplatin 7Fluorouracil 7Leucovorin 6pembrolizumab 4Paclitaxel 4Capecitabine 4Radiotherapy 3Radiation 3Nivolumab 3Cisplatin 3zimberelimab 2tislelizumab 2durvalumab 2Trastuzumab 2Taxes 2Levoleucovorin 2Irinotecan 2zanidatamab 1tucatinib 1trifluridine tipiracil drug combination 1tremelimumab 1trastuzumab deruxtecan 1spartalizumab 1quemliclustat 1obinutuzumab 1naptumomab estafenatox 1lenvatinib 1futibatinib 1dehydroftorafur 1cixutumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Adenocarcinoma Of Esophagus × Nivolumab × Clear all
NCT05568095 2026-06-02

STAR-221

Arcus Biosciences, Inc.

Phase 3 Active not recruiting
1,040 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT05480384 2026-04-21

Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction

Brown University

Phase 2 Active not recruiting
1 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

NCT06504615 2026-04-03

METAGIO

Bristol-Myers Squibb

Active not recruiting
208 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡